Verified Document

The Public Policy About Parkinsons Term Paper

Health Issues for the Aging One of the diseases that creates a burden on our health care system, especially among the aged, is Parkinson's disease. At present, there is no known cure for Parkinson's, merely treatments that can help to reduce the symptoms. This makes it difficult to develop a public health solution to Parkinson's. On the prevention side, one of the challenges is that while there have been some risk factors potentially identified, the reality is that there is no known cause either. For example, a meta-analysis suggest that living in a rural area, drinking well water, farming and exposure to pesticides all might be risk factors (Priyardashi et al, 2001). The current state of research at present is such that the different forms that Parkinson's takes are being studied (Peto, et al, 1995). Moreover, the different ways that Parkinson's presents can also bring about a number of different complications, from which the need for treatment arises. One example is that PD patients suffer from gastrointestinal issues at a higher rate than the general population – the link is known but the mechanisms by which this link occurs are not (Natale et al, 2008).

There have actually been a number of studies that show promise in getting to a cure for Parkinson's. One study showed that alpha-synuclein synaptic pathology might help in providing direction for a cure (Bellucci et al, 2012). Disruption of the brain-blood barrier may be a causal factor, and thus a pathway to a cure (Lee & Pienaar, 2014). A substantial body of research shows that cannabinoids are effective in treatment of Parkinson's symptoms, owing to the neuroprotective properties of cannabinoids (Carroll, Zeissler, Hanemann & Zajicek, 2012). Several studies of self-reporting Parkinson's patients support this, showing that many take cannabis to medicate, and that nearly half find this to be effective (Venderova et al, 2004).

Because so little is known about Parkinson's, most of the public policy response has been aimed at ensuring funding is available to researchers....

The primary body for disbursing this funding is the National Institute of Neurological Disorders and Stroke (NINDS), which in 2016 disbursed $107 million to various agencies that conduct Parkinson's research (NINDS, 2017). In total, NIH spent $161 million on Parkinson's research in 2016. Decreasing the burden of this disease is actually one of the mandates that NINDS has, so there is a clear understanding of the need to invest in Parkinson's research, because of the burden in presents on society and on the government.
The biggest issue where government policy is concerned is in managing the cost of Parkinson's treatment. There are a variety of treatments, ranging substantially in price. The most current treatment, Gocovri, has recently been approved, at a cost of $28,000 per year (Investors.com, 2017). In 2007, the direct medical cost of PD was $6.22 billion and overall economic impact was $10.78 billion. Of this, medications are $1.47 billion of direct costs (Valldeoriola, 2010). Other costs include nursing homes ($2.6 billion), caregivers ($2.36 billion), lost productivity ($1 billion). At that time, direct cost per patient was $12, 491 (Valldeoriola, 2010), much less than would be the case today with a patient on Gocovri.

Much of the direct costs come from Medicare, but some of the indirect costs will as well, and more will come from Veteran's Affairs. So there is significant financial incentive for the US to explore all options with respect to managing these costs. Yet, cannabis is still illegal at the federal level. There are several states where it is legal for medical purposes, yet the stated policy of the White House is to increase marijuana law enforcement (Liptak, 2017), which could reduce access to cannabinoids for PD sufferers, increase their costs or risks, and could curtail their rights to care even in states with medical marijuana laws.

The federal government's lack of willingness to explore all options for treating PD sufferers is baffling – the same government is willing to allow legal opioid production but…

Sources used in this document:

References

Belluci, A., Navarria, L., Zaltieri, M., Missale, C. & Spano, P. (2012). Alpha-synuclein synaptic pathology and its implications in the development of novel therapeutic approaches to cure Parkinson's disease. Brain Research. Vol. 1432 (2012) 95-113.

Carroll, C., Zeissler, M., Hanneman, C. & Zajicek, P. (2012). ?9-tetrahydrocannabinol (?9-THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson's disease. Neuropathy and Applied Neurobiology. Vol. 38 (2012) 535-547.

Investors.com (2017). Adamas Parkinson's drug is double the cost of analyst expectations. Investors' Business Daily Retrieved November 20, 2017 from https://www.investors.com/news/technology/adamas-parkinsons-drug-cost-is-double-analyst-expectations/

Lee, H. & Pienaar, I. (2014) Disruption of the blood-brain barrier in Parkinson's disease: Curse or a route to a cure? Frontiers in Bioscience. Vol. 19 (2014) 272-280.

Liptak, K. (2017). White House: Feds will step up marijuana law enforcement. CNN. Retrieved November 20, 2017 from http://www.cnn.com/2017/02/23/politics/white-house-marijuana-donald-trump-pot/index.html

Natale, G., Pasquali, L, Ruggieri, S., Paparelli, A. & Fornai, F. (2008). Parkinson's disease and the gut: A well-known clinical association in need of an effective cure and explanation. Neurogastroenterology and Motility. Vol. 20 (2008) 741-749.

NINDS (2017). Focus on Parkinson's disease research. NINDS.NIH.gov. Retrieved November 20, 2017 from https://www.ninds.nih.gov/Current-Research/Focus-Research/Focus-Parkinsons-Disease

Peto, V., Jenkinson, C., Fitzpatrick, R. & Greenhall, R. (1995) The development and validation of a short measure of functioning and well-being for individuals with Parkinson's disease. Quality of Life Research. Vol. 4 (3) 241-248.

Cite this Document:
Copy Bibliography Citation

Related Documents

Parkinson's Disease
Words: 3144 Length: 12 Document Type: Essay

Abstract This paper examines the impact of Parkinson’s disease on elderly (65+ years of age) Caucasian males. This is an underserved population in the U.S. 1% of all elderly persons suffer from Parkinson’s and 60% of them are of this underserved population. The paper discusses risk factors that may lead to the onset of this disease but recognizes that the etiology of Parkinson’s is still as of yet unknown. It examines

Bush Religion the Religious Policies
Words: 2536 Length: 8 Document Type: Research Proposal

Proponents of stem-cell research believe that it may be the secret to curing infertility, genetic imperfection and neurological degeneration, and on the premise of this supposition, have lobbied vigorously to prevent legislation that would protect embryos from harvest and use in research, espousing the idea that: "Criminalizing human reproductive cloning in the United States will only make it less safe and more costly for these infertile couples. They will be

FDA Health Policy on Intravesical
Words: 3065 Length: 10 Document Type: Research Paper

Phase II consists of efficacy trials of the drug, which are tested on volunteers of the target population. When everything goes right, the drug manufacturer discusses the development process, continued human testing, other concerns and protocols for phase III with the FDA. Phase III is the more extensive. It is at this time that the manufacture can work for the accelerated development and review of the drug. Treatment IND

Ncfr Practitioners Need to Cultivate an Ongoing
Words: 1187 Length: 4 Document Type: Essay

NCFR Practitioners need to cultivate an ongoing understanding of legal issues, and be aware of policy constraints on their practice. The National Council on Family Relations suggests that the well being of families and communities depends directly on practitioner awareness of support services available, public policy, and legal protection relevant to the target population (NCFR, 2011). NFCR (2011) Content Area 8 pertains to family law, public policy, and related issues. Research

Ethics Surrounding Human Embryonic Stem
Words: 5907 Length: 14 Document Type: Research Paper

Although these stem cells are only a few years old, they possess unlimited potential in terms of clinical research. Specifically, scientists are focusing their potential uses in transplant medicine in order to significantly reduce the level of both infections and overall organ rejection in organ transplant surgery. The potential for using stem cells is of vast clinical and medical importance. These cells could potentially allow scientists to learn what occurs

Political Influence Over Stem Cell
Words: 2905 Length: 10 Document Type: Thesis

Going back further, the same religious principals also inspired opposition to organ transplants and blood transfusions; before that, the Catholic Church strictly forbade any forensic scientific research, necessitating the need to dissect cadavers for medical education entirely in secret (Levine, 2008). Just as the news media are partially at fault today for their failure to distinguish legitimate concerns from ludicrous fears in connection with the ongoing political debate over American

Sign Up for Unlimited Study Help

Our semester plans gives you unlimited, unrestricted access to our entire library of resources —writing tools, guides, example essays, tutorials, class notes, and more.

Get Started Now